MyMedR

Displaying all 4 publications

Abstract:

Sort:

Natural Products as the Modulators of Oxidative Stress: An Herbal Approach in the Management of Prostate Cancer

Nelson VK, Pullaiah CP, Saleem Ts M, Roychoudhury S, Chinnappan S, Vishnusai B, et al.

Adv Exp Med Biol, 2022;1391:161-179.
PMID: 36472822 DOI: 10.1007/978-3-031-12966-7_10

Prostate cancer is the most commonly diagnosed and frequently occurred cancer in the males globally. The current treatment strategies available to treat prostate cancer are not much effective and express various adverse effects. Hence, there is an urgent need to identify novel treatment that can improve patient outcome. From times immemorial, natural products are highly recognized for novel drug development for various diseases including cancer. Cancer cells generally maintain higher basal levels of reactive oxygen species (ROS) when compared to normal cells due to its high metabolic rate. However, initiation of excess intracellular ROS production can not be tolerated by the cancer cells and induce several cell death signals which are in contrast to normal cells. Therefore, small molecules of natural origin that induce ROS can potentially kill cancer cells in specific and provide a better opportunity to develop a novel drug therapy. In this review, we elaborated various classes of medicinal compounds and their mechanism of killing prostate cancer cells through direct or indirect ROS generation. This can generate a novel thought to develop promising drug candidate to treat prostate cancer patients.
Exploring nalbuphine loaded chitosan nanoparticles for effective pain management through intranasal administration: a comparative study

Khanna K, Sharma N, Karwasra R, Kumar A, Nishad DK, Janakiraman AK, et al.

J Drug Target, 2024 Sep 04.
PMID: 39229894 DOI: 10.1080/1061186X.2024.2397800

BACKGROUND: Intranasal drug delivery shows potential for brain access via olfactory and trigeminal routes.
PURPOSE: This work aimed to ensure brain availability of nalbuphine via the nasal route.
METHOD: Chitosan based nanoparticles loaded with nalbuphine were successfully prepared using ionic gelation method and characterised.
RESULT: SEM results revealed that the nanoparticles were spherical in shape, with an average size of 192.4 ± 11.6 nm. Zeta potential and entrapment efficiency was found 32.8 mV and 88.43 ± 7.75%, respectively. The X-ray diffractometry and DSC results unravel a profound understanding on the physical and thermal characteristics. The in-vitro release of nalbuphine from the nanoparticles was biphasic, with an initial burst release followed by a slow-release profile. In-vitro cell study on HEK-293 cells and microscopic images of brain tissue confirmed the safety profile of formulation. In-vivo efficacy studies on animal confirmed the effectiveness of developed intranasal formulation as compared to the standard therapy. The in-vivo pharmacokinetic studies showed that the prepared nanoparticles were able to efficiently deliver nalbuphine to the brain in comparison to the other body organs. Gamma scintigraphy images showed retention of the drug in the brain. Furthermore, the efficacy studies confirmed that the nanoparticles were found significantly more effective than the marketed formulation in pain management.
Increased frequency of late-senescent T cells lacking CD127 in chronic hepatitis C disease

Barathan M, Mohamed R, Saeidi A, Vadivelu J, Chang LY, Gopal K, et al.

Eur J Clin Invest, 2015 May;45(5):466-74.
PMID: 25721991 DOI: 10.1111/eci.12429

Hepatitis C virus (HCV) causes persistent disease in ~85% of infected individuals, where the viral replication appears to be tightly controlled by HCV-specific CD8+ T cells. Accumulation of senescent T cells during infection results in considerable loss of functional HCV-specific immune responses.
The potency of hydrothermally prepared sulfated silica (SO4/SiO2) as a heterogeneous acid catalyst for ethanol dehydration into diethyl ether

Pratika RA, Wijaya K, Utami M, Mulijani S, Patah A, Alarifi S, et al.

Chemosphere, 2023 Nov;341:139822.
PMID: 37598950 DOI: 10.1016/j.chemosphere.2023.139822

The dehydration of ethanol into diethyl ether over a SO4/SiO2 catalyst was investigated. The SO4/SiO2 catalysts were prepared by the sulfation method using 1, 2, and 3 M of sulfuric acid (SS1, SS2, and SS3) via hydrothermal treatment. This study is focused on the synthesis of a SO4/SiO2 catalyst with high total acidity that can be subsequently utilized to convert ethanol into diethyl ether. The total acidity test revealed that the sulfation process increased the total acidity of SiO2. The SS2 catalyst (with 2 M sulfuric acid) displayed the highest total acidity of 7.77 mmol/g, whereas the SiO2 total acidity was only 0.11 mmol/g. Meanwhile, the SS3 catalyst (with 3 M sulfuric acid) has a lower total acidity of 7.09 mmol/g due to the distribution of sulfate groups on the surface having reached its optimum condition. The crystallinity and structure of the SS2 catalyst were not affected by the hydrothermal treatment or the sulfate process on silica. Furthermore, The SS2 catalyst characteristics in the presence of sulfate lead to a flaky surface in the morphology and non-uniform particle size. In addition, the surface area and pore volume of the SS2 catalyst decreased (482.56-172.26 m2/g) and (0.297-0.253 cc/g), respectively, because of the presence of sulfate on the silica surface. The SS2 catalyst's pore shape information explains the formation of non-uniform pore sizes and shapes. Finally, the activity and selectivity of SO4/SiO2 catalysts in the conversion of ethanol to diethyl ether yielded the highest ethanol conversion of 70.01% and diethyl ether product of 9.05% from the SS2 catalyst (the catalyst with the highest total acidity). Variations in temperature reaction conditions (175-225 °C) show an optimum reaction temperature to produce diethyl ether at 200 °C (11.36%).